Holen Sie sich die Stockscreener-App
12.54
16.43%
1.77
Vorhandelsmarkt:
12.98
0.44
+3.51%
Schlusskurs vom Vortag:
$10.77
Offen:
$10.5
24-Stunden-Volumen:
8.88M
Relative Volume:
3.60
Marktkapitalisierung:
$2.24B
Einnahmen:
$15.36M
Nettoeinkommen (Verlust:
$-276.48M
KGV:
-7.7748
EPS:
-1.6129
Netto-Cashflow:
$-235.87M
1W Leistung:
+23.91%
1M Leistung:
+28.09%
6M Leistung:
+140.23%
1J Leistung:
+403.61%
1-Tages-Spanne:
$10.48
$13.04
1-Wochen-Bereich:
$9.275
$13.04
52-Wochen-Spanne:
$1.775
$13.04
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
12.54 | 2.24B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Relay Therapeutics (RLAY) climbs 16% ahead of cancer treatment update - MSN
Aug Highlights: Can Relay Therapeutics Inc scale operations efficiently2026 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII.com
Relay Therapeutics, Inc. (RLAY) stock price, news, quote and history - Yahoo Finance Singapore
Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week HighTime to Buy? - MarketBeat
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Sahm
Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update - insidermonkey.com
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib at Vascular Anomalies Conference - National Today
5 Stocks With Easy 8-20% Gains - Insider Monkey
First zovegalisib results in about 20 vascular anomaly patients due in May - Stock Titan
Relay Therapeutics stock hits 52-week high at $11.52 By Investing.com - Investing.com Canada
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6.4%Here's What Happened - MarketBeat
Relay Therapeutics stock hits 52-week high at $11.52 - Investing.com
Earnings Update: Is Relay Therapeutics Inc likely to announce a buybackEarnings Overview Summary & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Will Relay Therapeutics Inc benefit from government policyQuarterly Profit Report & Community Consensus Picks - baoquankhu1.vn
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status - simplywall.st
RLAY SEC FilingsRelay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Relay Therapeutics (RLAY) price target increased by 17.50% to 17.43 - MSN
Vanguard realignment reports 0 Relay Therapeutics shares (RLAY) - Stock Titan
Aug Levels: Will Relay Therapeutics Inc benefit from green energy policies2026 Technical Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - AOL.com
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Relay Ther - GuruFocus
Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies - Traders Union
Aug Summary: Will Relay Therapeutics Inc benefit from government policy2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook for RLAY Q1 Earnings - MarketBeat
RLAY: HC Wainwright & Co. Raises Price Target to $19.00, Maintai - GuruFocus
H.C. Wainwright raises Relay Therapeutics price target on trial data By Investing.com - Investing.com Australia
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target on trial data - Investing.com
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Aug Update: What is the earnings history of Relay Therapeutics IncTrade Analysis Report & Target Return Focused Picks - baoquankhu1.vn
Relay Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Relay Therapeutics stock By Investing.com - Investing.com Canada
Profit Review: Can Relay Therapeutics Inc sustain its profitability2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Relay Therapeutics Price Target Raised to $17.00 - National Today
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):